Research ExplorerPublicationsAutoimmune hypophysitis secondary to therapy with immune che...

Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction

Standard

Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction. / Hartmann, Amelie; Paparoupa, Maria; Volkmer, Bjoern G; Rompel, Rainer; Wittig, Andreas; Schuppert, Frank.

In: J ONCOL PHARM PRACT, Vol. 26, No. 7, 10.2020, p. 1774-1779.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hartmann, A, Paparoupa, M, Volkmer, BG, Rompel, R, Wittig, A & Schuppert, F 2020, 'Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction', J ONCOL PHARM PRACT, vol. 26, no. 7, pp. 1774-1779. https://doi.org/10.1177/1078155220910202

APA

Hartmann, A., Paparoupa, M., Volkmer, B. G., Rompel, R., Wittig, A., & Schuppert, F. (2020). Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction. J ONCOL PHARM PRACT, 26(7), 1774-1779. https://doi.org/10.1177/1078155220910202

Vancouver

Hartmann A, Paparoupa M, Volkmer BG, Rompel R, Wittig A, Schuppert F. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction. J ONCOL PHARM PRACT. 2020 Oct;26(7):1774-1779. https://doi.org/10.1177/1078155220910202

Bibtex

@article{992a7c8d5f414de6a4a8d1420b4e2f7b,
title = "Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction",
abstract = "INTRODUCTION: Immune checkpoint inhibitors are becoming increasingly important in oncology. Immune-related adverse events, including autoimmune hypophysitis, have been reported before.CASE REPORT: We present a case series of three males and one female, suffering from either malignant melanoma or renal cell carcinoma, who developed hypophysitis under Nivolumab and/or Ipilimumab. A wide range of clinical manifestations from asymptomatic hypophysitis, headache, general weakness, loss of appetite, visual field impairment, and confusion to acute life-threatening Addison crisis was observed.Management and outcome: All patients received corticosteroids. Immune checkpoint inhibitors were discontinued in three cases until resolution of symptoms.DISCUSSION: The objective of our report is to raise the awareness of physicians, regarding this rare clinical entity, which may become life-threatening, if not promptly recognized and properly treated.",
author = "Amelie Hartmann and Maria Paparoupa and Volkmer, {Bjoern G} and Rainer Rompel and Andreas Wittig and Frank Schuppert",
year = "2020",
month = oct,
doi = "10.1177/1078155220910202",
language = "English",
volume = "26",
pages = "1774--1779",
journal = "J ONCOL PHARM PRACT",
issn = "1078-1552",
publisher = "SAGE Publications",
number = "7",

}

RIS

TY - JOUR

T1 - Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction

AU - Hartmann, Amelie

AU - Paparoupa, Maria

AU - Volkmer, Bjoern G

AU - Rompel, Rainer

AU - Wittig, Andreas

AU - Schuppert, Frank

PY - 2020/10

Y1 - 2020/10

N2 - INTRODUCTION: Immune checkpoint inhibitors are becoming increasingly important in oncology. Immune-related adverse events, including autoimmune hypophysitis, have been reported before.CASE REPORT: We present a case series of three males and one female, suffering from either malignant melanoma or renal cell carcinoma, who developed hypophysitis under Nivolumab and/or Ipilimumab. A wide range of clinical manifestations from asymptomatic hypophysitis, headache, general weakness, loss of appetite, visual field impairment, and confusion to acute life-threatening Addison crisis was observed.Management and outcome: All patients received corticosteroids. Immune checkpoint inhibitors were discontinued in three cases until resolution of symptoms.DISCUSSION: The objective of our report is to raise the awareness of physicians, regarding this rare clinical entity, which may become life-threatening, if not promptly recognized and properly treated.

AB - INTRODUCTION: Immune checkpoint inhibitors are becoming increasingly important in oncology. Immune-related adverse events, including autoimmune hypophysitis, have been reported before.CASE REPORT: We present a case series of three males and one female, suffering from either malignant melanoma or renal cell carcinoma, who developed hypophysitis under Nivolumab and/or Ipilimumab. A wide range of clinical manifestations from asymptomatic hypophysitis, headache, general weakness, loss of appetite, visual field impairment, and confusion to acute life-threatening Addison crisis was observed.Management and outcome: All patients received corticosteroids. Immune checkpoint inhibitors were discontinued in three cases until resolution of symptoms.DISCUSSION: The objective of our report is to raise the awareness of physicians, regarding this rare clinical entity, which may become life-threatening, if not promptly recognized and properly treated.

U2 - 10.1177/1078155220910202

DO - 10.1177/1078155220910202

M3 - SCORING: Journal article

C2 - 32164491

VL - 26

SP - 1774

EP - 1779

JO - J ONCOL PHARM PRACT

JF - J ONCOL PHARM PRACT

SN - 1078-1552

IS - 7

ER -